Positive phase III results: Valneva is submitting vaccine for approval in Great Britain, which could come there later this year. However, the pharmacologist at MedUni Vienna puts the results into perspective.
Text The Austro-French vaccine manufacturer Valneva announced encouraging results of its phase III study of the Covid vaccine VLA2001 carried out in Great Britain on Monday. On average, the vaccine candidate led to the formation of more antibodies against the SARS-CoV-2 virus than was the case with the AstraZeneca vaccine. VLA2001 has also shown itself to be “generally well tolerated”, according to a broadcast.
With its Covid-19 vaccine, Valneva is pursuing the dead vaccine approach that has been tried and tested for decades: The entire killed virus is presented to the body. Consequently …
Accessed on October 18, 2021 at 02:17 am on https://www.sn.at/panorama/wissen/erster-totimpfstoff-zulassung-fuer-valneva-in-der-eu-anfang-2022-moeglich-111063358
